Funding for this research was provided by:
Austrian Science Fund (F4414, W1206-08, I2102)
FP7 Health (603646)
Received: 24 March 2020
Accepted: 8 September 2020
First Online: 24 September 2020
Ethics approval and consent to participate
: All in vivo experiments were approved by the Ethics Board at the Federal Ministry of Science and Research, Austria (permission BMWFW-66.011/0122-WF/V/3b/2014). Human subjects’ consent to participate is not applicable.
: All contributing authors have given their consent for the publication of this study.
: GG, SS, and GS were employees of AFFIRIS AG at the time of performance of the study. AFFIRIS AG holds a proprietary patent of the AFFITOME<b>®</b> technology for the generation of the vaccines. AG, AL, SR and CG are inventors in a patent related to the compound Anle138b. AG and CG are shareholders and co-founders of MODAG GmbH. AG is full-time employee, AL and SR are part-time employees of MODAG GmbH.